However, it is essential to note that when additional pharmacological intervention is required to control diabetes mellitus, the choice between SGLT-2 inhibitors and GLP-1 RAs should be based on the patient’s individual needs and the specific medications already being used. The gene discussed is GCG; the disease is diabetes mellitus.